Gemcitabine (dFdCTP) is a new Nucleoside anticancer that is an analog of Deoxycytidine. It is a pro-drug, and once transported into the cell, must be phosphorylated by Deoxycytidine kinase to an active form.

Both Gemcitabine diphosphate (dFdCTP) and Gemcitabine triphosphate (dFdCTP) inhibit processes required for DNA synthesis. Incorporation of dFdCTP into DNA is most likely the major mechanism by which Gemcitabine causes cell death.

Potential Indication

Gemcitabine is approved by the FDA for treatment of:

  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Ovarian Cancer
  • 200 mg
  • 1g
  • 2g